Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Vertex Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Vertex Pharmaceuticals Inc. closed $106.51 short of its 52-week high ($519.88), which the company reached on November 8th.
Yahoo Finance5d
Vertex Pharmaceuticals Incorporated (VRTX)
Zai Lab (ZLAB) and Vertex Pharmaceuticals (VRTX ... Macau SAR, Taiwan region and Singapore. Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF and APRIL being studied ...
Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement
Zai Lab (ZLAB) and Vertex Pharmaceuticals (VRTX) announced an exclusive collaboration and license agreement for the development and ...
The Pharma Letter4d
Vertex out-licenses povetacicept to Zai Lab
US biopharma Vertex Pharmaceuticals has entered an exclusive collaboration and license agreement with China’s Zai Lab for the ...
CRISPR-based Gene Editing Market Report 2025, with Company Profiles of the Top 10+ Major Market Players
The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...